trending Market Intelligence /marketintelligence/en/news-insights/trending/ATvFH2Rt0twp5K_kIHb57w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

US FDA proposes to withdraw approval of 249 abbreviated new drug applications

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

US FDA proposes to withdraw approval of 249 abbreviated new drug applications

The U.S. Food and Drug Administration has proposed withdrawing the approval of 249 abbreviated new drug applications filed by various companies.

An abbreviated new drug application, or ANDA, seeks approval for a generic version for an existing licensed medication or approved drug. Companies filing for an ANDA must demonstrate that their product works in the same manner as the approved drug.

The FDA's Center for Drug Evaluation and Research made the decision due to the companies repeatedly failing to file required annual reports for these applications.

Companies whose applications were flagged in a notice posted on the Federal Register include Abbott Laboratories, Pfizer Inc. and Johnson & Johnson.

The companies have an option to request a hearing by Feb. 10, or they could opt to submit all data, information and analyses upon which the request for a hearing relies by March 9.